Percutaneous Coronary Intervention

Ticagrelor (Brilinta, AstraZeneca) as orodispersible tablet vs. standard coated tablet for patients with ACS undergoing PCI.

During the COVID-19 pandemic, Medicare beneficiaries presented less frequently to hospitals for acute MI and stroke compared with 2018 and 2019, according to new research published in JAMA Cardiology.

The proportion of patients with same-day discharge after elective PCI has increased in the past decade, and researchers for a new study found that the increase is not associated with poorer 30-day mortality or rehospitalization.

After a significant decline in elective PCIs performed from 2010 to 2013, rates of the procedure remained stable through 2017, resulting in a roughly 10% decline in PCIs performed during the 8-year period, researchers reported.

For Indigenous Australians, PCI procedures performed at larger urban and regional centers were associated with increased risk for mortality and adverse cardiac events, independent of socioeconomic status and geographical remoteness.

Platelet inhibition with ticagrelor in an orodispersible tablet was similar to its standard coated form in patients with ACS undergoing PCI, according to results of the TASTER trial.

Fractional flow reserve-guided strategy vs. angiography-guided strategy for PCI in patients with STEMI and multivessel disease.

Regardless of patient age, switching from dual antiplatelet therapy to ticagrelor monotherapy after 3 months of ticagrelor plus aspirin reduces bleeding without increasing ischemic events, according to new data from the TWILIGHT trial.

New research from the ISAR-REACT 5 trial indicated that patients with ACS who received PCI had a lower composite endpoint of all-cause death, MI or stroke when given prasugrel vs. ticagrelor therapy.

Among interventional cardiologists, operator sex did not influence risk-adjusted mortality or morbidity, although female operators scored higher on appropriateness metrics and prescribed more guideline-directed medical therapy.